Format

Send to

Choose Destination
See comment in PubMed Commons below
Ophthalmologica. 2011;225(2):81-8. doi: 10.1159/000317908. Epub 2010 Sep 24.

Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia.

Author information

1
Department of Ophthalmology, Faculty of Medicine, Hospital São João, University of Porto, Porto, Portugal.

Abstract

AIM:

Evaluation of safety and efficacy of intravitreal ranibizumab in the treatment of choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration (AMD) or pathological myopia (PM).

METHODS:

Retrospective and multicentric analysis of 21 eyes with CNV. Nine eyes had angioid streaks, 5 inflammatory chorioretinal diseases, 3 central serous chorioretinopathy and 4 idiopathic CNV. Follow-ups lasted ≥3 months. Best-corrected visual acuity (BCVA), ocular coherence tomography (OCT) and fundus examination were assessed monthly.

RESULTS:

Sixteen eyes (76%) completed 180 days of follow-up. Overall BCVA increased by +9.8 letters with treatment (p = 0.015). Visual acuity improvements ≥15 letters occurred in 43%. A significant reduction in OCT central thickness was observed. No cases of severe visual acuity loss, systemic or ocular side effects were registered.

CONCLUSION:

Short-term results of intravitreal ranibizumab for CNV unrelated to AMD or PM are encouraging. This treatment may constitute the only option for some of these patients.

PMID:
20881442
DOI:
10.1159/000317908
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Support Center